Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): Teva-Terazosin (02230807). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.

TERAZOSIN HCL

8 general benefit · 4 not a benefit

Apo-Terazosin · DIN 02234502 · 1mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Terazosin · DIN 02234502 Manufacturer: Apotex Inc.; listing date 1998-12-31 Daily cost (source): $0.3938 Health Canada: Marketed since 2021-09-23 · brand APO-TERAZOSIN · ATC G04CA03 TERAZOSIN · form Tablet · route Oral · ingredients TERAZOSIN (TERAZOSIN HYDROCHLORIDE) 1 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Terazosin: Formulary list price $0.3938/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3938 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=55839 · Verify on the e-Formulary ↗ (DIN 02234502)

Source record
DIN 02234502: Apo-Terazosin Raw flags: chronicUseMed=Y, sec3=Y Item: 240800131; group id 355; item number 0820; lccId None; manufacturer id APX Source form: Tab; strength: 1mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3938; ministry $0.3938 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02234502 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=55839
Interchangeable products
Hytrin · DIN 00818658 · not recorded PMS-Terazosin · DIN 02243518 · $0.3938
Shortage status: resolved shortage (ended 2024-04-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02234502
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Terazosin · DIN 02243518 · 1mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Terazosin · DIN 02243518 Manufacturer: Pharmascience Inc.; listing date 2001-10-11 Daily cost (source): $0.3938 Health Canada: Marketed since 2001-02-23 · brand PMS-TERAZOSIN · ATC G04CA03 TERAZOSIN · form Tablet · route Oral · ingredients TERAZOSIN (TERAZOSIN HYDROCHLORIDE) 1 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Terazosin: Formulary list price $0.3938/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3938 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67437 · Verify on the e-Formulary ↗ (DIN 02243518)

Source record
DIN 02243518: PMS-Terazosin Raw flags: chronicUseMed=Y, sec3=Y Item: 240800131; group id 355; item number 0820; lccId None; manufacturer id PMS Source form: Tab; strength: 1mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3938; ministry $0.3938 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243518 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67437
Interchangeable products
Apo-Terazosin · DIN 02234502 · $0.3938 Hytrin · DIN 00818658 · not recorded
Shortage status: resolved shortage (ended 2018-10-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02243518
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Terazosin · DIN 02234503 · 2mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Terazosin · DIN 02234503 Manufacturer: Apotex Inc.; listing date 1998-12-31 Daily cost (source): $0.5005 Health Canada: Marketed since 2021-09-23 · brand APO-TERAZOSIN · ATC G04CA03 TERAZOSIN · form Tablet · route Oral · ingredients TERAZOSIN (TERAZOSIN HYDROCHLORIDE) 2 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Terazosin: Formulary list price $0.5005/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5005 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=55840 · Verify on the e-Formulary ↗ (DIN 02234503)

Source record
DIN 02234503: Apo-Terazosin Raw flags: chronicUseMed=Y, sec3=Y Item: 240800132; group id 355; item number 0821; lccId None; manufacturer id APX Source form: Tab; strength: 2mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.5005; ministry $0.5005 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02234503 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=55840
Interchangeable products
Hytrin · DIN 00818682 · not recorded PMS-Terazosin · DIN 02243519 · $0.5005
Shortage status: resolved shortage (ended 2024-05-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02234503
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Terazosin · DIN 02243519 · 2mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Terazosin · DIN 02243519 Manufacturer: Pharmascience Inc.; listing date 2001-10-11 Daily cost (source): $0.5005 Health Canada: Marketed since 2001-02-23 · brand PMS-TERAZOSIN · ATC G04CA03 TERAZOSIN · form Tablet · route Oral · ingredients TERAZOSIN (TERAZOSIN HYDROCHLORIDE) 2 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Terazosin: Formulary list price $0.5005/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5005 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67438 · Verify on the e-Formulary ↗ (DIN 02243519)

Source record
DIN 02243519: PMS-Terazosin Raw flags: chronicUseMed=Y, sec3=Y Item: 240800132; group id 355; item number 0821; lccId None; manufacturer id PMS Source form: Tab; strength: 2mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.5005; ministry $0.5005 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243519 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67438
Interchangeable products
Apo-Terazosin · DIN 02234503 · $0.5005 Hytrin · DIN 00818682 · not recorded
Shortage status: resolved shortage (ended 2018-11-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02243519
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Terazosin · DIN 02234504 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Terazosin · DIN 02234504 Manufacturer: Apotex Inc.; listing date 1998-12-31 Daily cost (source): $0.6797 Health Canada: Marketed since 2021-09-23 · brand APO-TERAZOSIN · ATC G04CA03 TERAZOSIN · form Tablet · route Oral · ingredients TERAZOSIN (TERAZOSIN HYDROCHLORIDE) 5 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Terazosin: Formulary list price $0.6797/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6797 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=55841 · Verify on the e-Formulary ↗ (DIN 02234504)

Source record
DIN 02234504: Apo-Terazosin Raw flags: chronicUseMed=Y, sec3=Y Item: 240800133; group id 355; item number 0822; lccId None; manufacturer id APX Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.6797; ministry $0.6797 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02234504 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=55841
Interchangeable products
Hytrin · DIN 00818666 · not recorded PMS-Terazosin · DIN 02243520 · $0.6797
Shortage status: resolved shortage (ended 2024-05-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02234504
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Terazosin · DIN 02243520 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Terazosin · DIN 02243520 Manufacturer: Pharmascience Inc.; listing date 2001-10-11 Daily cost (source): $0.6797 Health Canada: Marketed since 2001-02-23 · brand PMS-TERAZOSIN · ATC G04CA03 TERAZOSIN · form Tablet · route Oral · ingredients TERAZOSIN (TERAZOSIN HYDROCHLORIDE) 5 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Terazosin: Formulary list price $0.6797/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6797 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67439 · Verify on the e-Formulary ↗ (DIN 02243520)

Source record
DIN 02243520: PMS-Terazosin Raw flags: chronicUseMed=Y, sec3=Y Item: 240800133; group id 355; item number 0822; lccId None; manufacturer id PMS Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.6797; ministry $0.6797 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243520 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67439
Interchangeable products
Apo-Terazosin · DIN 02234504 · $0.6797 Hytrin · DIN 00818666 · not recorded
Shortage status: resolved shortage (ended 2022-09-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02243520
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Terazosin · DIN 02234505 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Terazosin · DIN 02234505 Manufacturer: Apotex Inc.; listing date 1998-12-31 Daily cost (source): $0.9950 Health Canada: Marketed since 2021-09-23 · brand APO-TERAZOSIN · ATC G04CA03 TERAZOSIN · form Tablet · route Oral · ingredients TERAZOSIN (TERAZOSIN HYDROCHLORIDE) 10 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Terazosin: Formulary list price $0.9950/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9950 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=55842 · Verify on the e-Formulary ↗ (DIN 02234505)

Source record
DIN 02234505: Apo-Terazosin Raw flags: chronicUseMed=Y, sec3=Y Item: 240800213; group id 355; item number 0823; lccId None; manufacturer id APX Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.9950; ministry $0.9950 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02234505 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=55842
Interchangeable products
Hytrin · DIN 00818674 · not recorded PMS-Terazosin · DIN 02243521 · $0.9950
Shortage status: resolved shortage (ended 2026-09-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02234505
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Terazosin · DIN 02243521 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Terazosin · DIN 02243521 Manufacturer: Pharmascience Inc.; listing date 2001-10-11 Daily cost (source): $0.9950 Health Canada: Marketed since 2001-02-23 · brand PMS-TERAZOSIN · ATC G04CA03 TERAZOSIN · form Tablet · route Oral · ingredients TERAZOSIN (TERAZOSIN HYDROCHLORIDE) 10 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Terazosin: Formulary list price $0.9950/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9950 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67440 · Verify on the e-Formulary ↗ (DIN 02243521)

Source record
DIN 02243521: PMS-Terazosin Raw flags: chronicUseMed=Y, sec3=Y Item: 240800213; group id 355; item number 0823; lccId None; manufacturer id PMS Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.9950; ministry $0.9950 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243521 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67440
Interchangeable products
Apo-Terazosin · DIN 02234505 · $0.9950 Hytrin · DIN 00818674 · not recorded
Shortage status: resolved shortage (ended 2025-05-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02243521
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Hytrin · DIN 00818658 · 1mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2016-02-19 — choose a marketed DIN from the same-category list.Discontinued 2016-02-19 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2016-02-19 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2016-02-19 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Hytrin · DIN 00818658 Manufacturer: Abbott Laboratories Limited; listing date 1996-10-01 Daily cost (source): $0.3938 Health Canada: Cancelled post market since 2016-02-19 · brand HYTRIN · ATC G04CA03 TERAZOSIN · form Tablet · route Oral · ingredients TERAZOSIN HYDROCHLORIDE 1 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Hytrin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9618 · Verify on the e-Formulary ↗ (DIN 00818658)

Source record
DIN 00818658: Hytrin Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240800131; group id 355; item number 0820; lccId None; manufacturer id ABB Source form: Tab; strength: 1mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00818658 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9618
Interchangeable products
Apo-Terazosin · DIN 02234502 · $0.3938 PMS-Terazosin · DIN 02243518 · $0.3938
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00818658
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2016-02-19 — choose a marketed DIN from the same-category list.

Hytrin · DIN 00818682 · 2mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2016-02-19 — choose a marketed DIN from the same-category list.Discontinued 2016-02-19 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2016-02-19 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2016-02-19 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Hytrin · DIN 00818682 Manufacturer: Abbott Laboratories Limited; listing date 1996-10-01 Daily cost (source): $0.5005 Health Canada: Cancelled post market since 2016-02-19 · brand HYTRIN · ATC G04CA03 TERAZOSIN · form Tablet · route Oral · ingredients TERAZOSIN HYDROCHLORIDE 2 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Hytrin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9619 · Verify on the e-Formulary ↗ (DIN 00818682)

Source record
DIN 00818682: Hytrin Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240800132; group id 355; item number 0821; lccId None; manufacturer id ABB Source form: Tab; strength: 2mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00818682 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9619
Interchangeable products
Apo-Terazosin · DIN 02234503 · $0.5005 PMS-Terazosin · DIN 02243519 · $0.5005
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00818682
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2016-02-19 — choose a marketed DIN from the same-category list.

Hytrin · DIN 00818666 · 5mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-05-16 — choose a marketed DIN from the same-category list.Discontinued 2017-05-16 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-05-16 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2017-05-16 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Hytrin · DIN 00818666 Manufacturer: Abbott Laboratories Limited; listing date 1996-10-01 Daily cost (source): $0.6797 Health Canada: Cancelled post market since 2017-05-16 · brand HYTRIN · ATC G04CA03 TERAZOSIN · form Tablet · route Oral · ingredients TERAZOSIN HYDROCHLORIDE 5 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Hytrin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9542 · Verify on the e-Formulary ↗ (DIN 00818666)

Source record
DIN 00818666: Hytrin Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240800133; group id 355; item number 0822; lccId None; manufacturer id ABB Source form: Tab; strength: 5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00818666 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9542
Interchangeable products
Apo-Terazosin · DIN 02234504 · $0.6797 PMS-Terazosin · DIN 02243520 · $0.6797
Shortage status: discontinued (2017-04-24, reported by BGP PHARMA ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00818666
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2017-05-16 — choose a marketed DIN from the same-category list.

Hytrin · DIN 00818674 · 10mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2016-02-19 — choose a marketed DIN from the same-category list.Discontinued 2016-02-19 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2016-02-19 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2016-02-19 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Hytrin · DIN 00818674 Manufacturer: Abbott Laboratories Limited; listing date 1996-10-01 Daily cost (source): $0.9950 Health Canada: Cancelled post market since 2016-02-19 · brand HYTRIN · ATC G04CA03 TERAZOSIN · form Tablet · route Oral · ingredients TERAZOSIN HYDROCHLORIDE 10 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Hytrin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12778 · Verify on the e-Formulary ↗ (DIN 00818674)

Source record
DIN 00818674: Hytrin Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240800213; group id 355; item number 0823; lccId None; manufacturer id ABB Source form: Tab; strength: 10mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00818674 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12778
Interchangeable products
Apo-Terazosin · DIN 02234505 · $0.9950 PMS-Terazosin · DIN 02243521 · $0.9950
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00818674
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2016-02-19 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered

Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CAPTOPRIL, CILAZAPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL, RAMIPRIL & HYDROCHLOROTHIAZIDE, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL 24:08 Hypotensive Drugs (For Diuretics See 40:28)

ATENOLOL & CHLORTHALIDONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab

BENAZEPRIL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

CANDESARTAN CILEXETIL

· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab

CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE

· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab

CAPTOPRIL

· 14 products · Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab

CILAZAPRIL

· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab

CILAZAPRIL & HYDROCHLOROTHIAZIDE

· 2 products · General benefit · strengths: 5mg/12.5mg · Tab

CLONIDINE HCL

· 17 products · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8) · strengths: 0.025mg, 0.1mg, 0.2mg · Tab

DOXAZOSIN MESYLATE

· 12 products · Listed, not a benefit (3), General benefit (9) · strengths: 1mg, 2mg, 4mg · Tab

ENALAPRIL MALEATE

· 52 products · Listed, not a benefit (1), General benefit (51) · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab

FELODIPINE

· 12 products · General benefit (10), Listed, not a benefit (2) · strengths: 2.5mg, 5mg, 10mg · ER Tab, SR Tab

FOSINOPRIL SODIUM

· 12 products · Listed, not a benefit (2), General benefit (10) · strengths: 10mg, 20mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:08 and 35 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: hypertension, symptoms of benign prostatic hyperplasia
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE ACEBUTOLOL HCL · Listed, not a benefit (3), General benefit (6) INDICATIONS AND CLINICAL USE APO-ACEBUTOLOL is indicated for the following:  Treatment of mild to moderate hypertension.  Long-term management of patients with angina pectoris due to ischemic heart disease. PM: https://pdf.hres.ca/dpd_pm/00047998.PDF; date October 24, 2018; DIN 02147602; fetched 2026-09-10 Product monograph AMLODIPINE · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) 1 INDICATIONS NORVASC (amlodipine besylate tablets) is indicated for: • Hypertension NORVASC is indicated in the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00071908.PDF; date AUG 02, 2023; DIN 00878928; fetched 2026-09-10 Product monograph AZILSARTAN MEDOXOMIL · Off-Formulary Interchangeable, not an ODB benefit 1 Part 1: Healthcare Professional Information Indications • EDARBI (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) indicated for the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00082489.PDF; date 2025-10-24; DIN 02381389; fetched 2026-09-10 Product monograph BENAZEPRIL · Listed, not a benefit (3), General benefit (3) Indications BENAZEPRIL (benazepril hydrochloride tablets) is indicated for:  Treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00080887.PDF; date 2025-06-24; DIN 02273918; fetched 2026-09-10 Product monograph CANDESARTAN CILEXETIL · General benefit • Heart Failure o The treatment of NYHA Class II and III heart failure with ejection fraction ≤ 40% in addition to standard therapy, with or without an ACE inhibitor. 1.1 Pediatrics Pediatrics (6 to 17 years of age): • Hypertension ATACAND is indicated for the treatment of essential hypertension in children and adolescents 6 to 17 years of age (see 7.1.3 Pediatrics, 14 CLINICAL TRIALS). PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10 Product monograph • Hypertension PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10 Product monograph CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE · General benefit 1 INDICATIONS ATACAND PLUS (candesartan cilexetil/hydrochlorothiazide) is indicated for: • the treatment of essential hypertension in patients for whom combination therapy is appropriate. PM: https://pdf.hres.ca/dpd_pm/00076288.PDF; date JUN 18, 2001; DIN 02244021; fetched 2026-09-10 Product monograph CHLORTHALIDONE · Listed, not a benefit (1), General benefit (2) 1 INDICATIONS APO-CHLORTHALIDONE (chlorthalidone) is indicated for: • Treatment of hypertension. PM: https://pdf.hres.ca/dpd_pm/00069909.PDF; date MAR 14, 2023; DIN 00360279; fetched 2026-09-10 Product monograph CILAZAPRIL & HYDROCHLOROTHIAZIDE · General benefit 1 INDICATIONS INHIBACE PLUS (cilazapril and hydrochlorothiazide) is indicated for:  treatment of mild to moderate essential hypertension in patients for whom combination therapy with both cilazapril and hydrochlorothiazide is appropriate. PM: https://pdf.hres.ca/dpd_pm/00066994.PDF; date September 07, 1995; DIN 02181479; fetched 2026-09-10 Product monograph CLONIDINE HCL · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8) INDICATIONS AND CLINICAL USE TEVA-CLONIDINE (clonidine hydrochloride) is indicated for the treatment of hypertension. PM: https://pdf.hres.ca/dpd_pm/00024986.PDF; date April 25, 2014; DIN 02046121; fetched 2026-09-10 Product monograph DOXAZOSIN MESYLATE · Listed, not a benefit (3), General benefit (9) Benign Prostatic Hyperplasia (BPH) APO-DOXAZOSIN is also indicated for the treatment of symptoms of benign prostatic hyperplasia (BPH). PM: https://pdf.hres.ca/dpd_pm/00048001.PDF; date October 29, 2018; DIN 02240588; fetched 2026-09-10 Product monograph and 21 more Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE APO-TERAZOSIN (terazosin hydrochloride) is indicated for: - the treatment of mild to moderate hypertension. - the treatment of symptoms of benign prostatic hyperplasia (BPH). Hypertension APO-TERAZOSIN (terazosin hydrochloride) is employed in a general treatment program in conjunction with a thiazide diuretic and/or other antihypertensive drugs as needed for proper patient response. APO-TERAZOSIN may be tried as a sole therapy in those patients in whom other agents caused adverse effects or are inappropriate. Benign Prostatic Hyperplasia The onset of effect is rapid, with improvement in peak flow rate and symptoms observed at 2 weeks. The effect on these variables was well maintained throughout the study duration (18 months). APO- TERAZOSIN does not retard or stop the progression of benign prostatic hyperplasia (BPH). The long-term effects of terazosin hydrochloride on the incidence of surgery, acute urinary obstruction or other complications of BPH, are yet to be determined. Page 3 of 42 A number of clinical conditions can mimic symptomatic BPH (i.e. … https://pdf.hres.ca/dpd_pm/00063013.PDF PM date: September 16, 2021 Source product: APO-TERAZOSIN; DIN 02234502; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Hytrin · DIN 00818666 Shortage status: discontinued (2017-04-24, reported by BGP PHARMA ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00818666

Check this DIN again

Other review policies

For Hytrin: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026